Trial Profile
A retrospective study evaluating efficacy and safety of Icotinib and whole-brain radiotherapy (IWBRT) in patients with brain metastases from EGFR-mutant non-small cell lung cancer
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 11 May 2018
Price :
$35
*
At a glance
- Drugs Icotinib (Primary)
- Indications Brain metastases; Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- 11 May 2018 New trial record
- 01 Apr 2018 Results published in the Medicine